Skip to Content


Active Substance: ferumoxytol
Common Name: ferumoxytol
ATC Code: B03
Marketing Authorisation Holder: Takeda Pharma A/S
Active Substance: ferumoxytol
Status: Withdrawn
Authorisation Date: 2012-06-15
Therapeutic Area: Anemia Kidney Failure, Chronic
Pharmacotherapeutic Group: Anti-anaemic preparations

Therapeutic Indication

Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).

The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).

The marketing authorisation for Rienso has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.